市場概況

The global Microneedle Drug Delivery Systems Market is anticipated to experience significant growth, expanding from USD 2.59 億で 2022 米ドルへ 3.82 10億まで 2029, at a CAGR of 5.5% の予測期間中に 2023-2029. Microneedle drug delivery systems offer a non-invasive and painless approach to administering drugs and vaccines. These systems utilize tiny needles to create micro-pores on the skin, enabling efficient and targeted drug delivery. The market was notably impacted by the COVID-19 pandemic, which prompted the development of innovative skin patches for drug delivery purposes. Companies operating in the market are actively focusing on the advancement of microneedle patches and drug delivery systems.

The increasing prevalence of chronic diseases, such as diabetes and cardiovascular disorders, has created a pressing need for efficient and convenient drug delivery methods. Microneedle systems offer a safer and more patient-friendly alternative to traditional injections, contributing to their rising adoption.

さらに, advancements in painless drug delivery research and technological progress have significantly enhanced the efficacy and usability of microneedle drug delivery systems. These advancements have garnered attention from both healthcare professionals and patients, further propelling market growth.

The growing diabetic population and the rise in chronic diseases worldwide have also fueled the demand for microneedle drug delivery systems. These systems provide a convenient and efficient means of administering medications, particularly for individuals who require frequent injections.

さらに, ongoing research studies on microneedles and the introduction of new product launches have further stimulated market growth. Market players are actively investing in research and development activities to expand the application areas of microneedle drug delivery systems and improve their performance.

しかし, the market does face certain limitations that may impede its growth. The availability of approved products in the market is relatively limited, posing challenges for widespread adoption. さらに, potential complications associated with microneedles, such as skin irritation or infection, need to be carefully addressed to ensure patient safety and confidence.

市場セグメンテーション

The market is segmented based on product type, 応用, そして地理.

Segmentation by Product Type
Solid
Hollow
Coated
Dissolvable

Segmentation by Application
Drug Delivery
Vaccine Delivery
Dermatology
その他

地理によるセグメンテーション
北米 – アメリカ, カナダ, and Mexico
ヨーロッパ – イギリス, ドイツ, フランス, イタリア, スペイン, およびその他のヨーロッパ
アジア太平洋地域 – 中国, 日本, 韓国, インド, オーストラリア, およびその他のアジア太平洋地域
世界のその他の地域

The microneedle drug delivery market is expected to grow in vaccine delivery due to the increasing prevalence of influenza and viral infections. Microneedle vaccinations have shown effectiveness in generating a strong immune response by delivering vaccines efficiently to immune cell-rich skin regions. The use of sustained-release polymers or integrated microparticles and nanoparticles in microneedles can eliminate the need for multiple vaccinations, increasing demand for such vaccine delivery systems. さらに, company focus on business strategies like mergers and collaborations, along with more vaccine launches, will contribute to the growth of the vaccine delivery segment.

The North American market for microneedle drug delivery systems is expected to grow due to the rising prevalence of chronic, skin, and infectious diseases. Technological advancements in microneedle fabrication further promote adoption. The region’s burden of chronic diseases and high flu cases drive demand for microneedle drug delivery. Strategic initiatives like collaborations contribute to market growth. In conclusion, the microneedle drug delivery market, especially for vaccines, will see significant growth due to infectious diseases, technological advancements, and strategic initiatives.

競争環境

The market for microneedle drug delivery systems is fragmented and highly competitive, with a few major players holding dominant market share. Key companies in this market include Becton, ディキンソン アンド カンパニー, Candela Corporation, Corium Inc., CosMED Pharmaceutical Co., 株式会社, Debiotech S.A., LTS Lohmann Therapie-Systeme AG, Micropoint Technologies Pte Ltd, nanoBioSciences, LLC (DBA AdminMed), NanoPass Technologies Ltd., Raphas Co., 株式会社, とりわけ.

最近の業界の発展

In October 2022, Emergex Vaccines Holding Limited successfully acquired Zosano Pharma Corporation’s assets. These assets include valuable intellectual property, license agreements, manufacturing equipment, and Zosano’s proprietary microneedle array patch (MAP) intradermal drug delivery system. The acquisition also included rights to solid-coated microneedle array patch technology, formulation and coating methods, and specialized equipment.

CGBio, a South Korean healthcare provider, launched CGDew Derma Regen, a new skin care patch in November 2022. The patch is part of their microneedle pipeline and is made from various materials such as silicon, チタン, ステンレス鋼, and polymers. It aims to improve medication diffusion by creating tiny pores on the skin.

このレポートを選択する理由

Gain a reliable outlook of the global microneedle drug delivery systems market forecasts from 2023 に 2029 シナリオ全体にわたって.
投資対象となる成長セグメントを特定する.
会社概要と市場データを通じて競合他社に先んじる.
Excel 形式でのシナリオ全体の分析を容易にするための市場予測.
3ヶ月間の戦略コンサルティングとリサーチサポート.
シングルユーザーライセンスに提供される印刷認証.